.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Julphar
Merck
Covington
Cerilliant
Queensland Health
Chinese Patent Office
Moodys
Dow
US Army

Generated: November 20, 2017

DrugPatentWatch Database Preview

Granisetron - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for granisetron and what is the scope of granisetron patent protection?

Granisetron
is the generic ingredient in six branded drugs marketed by Heron Theraps Inc, Kyowa Kirin, Roche, Sandoz Inc, West-ward Pharms Int, Taro Pharm, Akorn Inc, Barr, Fresenius Kabi Usa, Mylan, Hikma Farmaceutica, Pediatrx, Sagent Strides, Sagent Agila, Cipla Ltd, Aurobindo Pharma Ltd, Apotex Inc, Dr Reddys Labs Ltd, Mylan Labs Ltd, Epic Pharma Llc, Bionpharma Inc, Teva Pharms Usa, Wockhardt Usa, Natco Pharma, Luitpold, Orchid Hlthcare, Teva Pharms, and Baxter Hlthcare Corp, and is included in fifty NDAs. There are seven patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Granisetron has fifty-six patent family members in thirty-two countries.

There are twenty-six drug master file entries for granisetron. Three suppliers are listed for this compound.

Pharmacology for granisetron

Medical Subject Heading (MeSH) Categories for granisetron

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sandoz Inc
GRANISETRON HYDROCHLORIDE
granisetron hydrochloride
INJECTABLE;INJECTION078835-001Jun 30, 2008APRXNoNo► Subscribe► Subscribe► Subscribe
Sagent Strides
GRANISETRON HYDROCHLORIDE
granisetron hydrochloride
INJECTABLE;INJECTION091136-001Apr 9, 2010APRXNoNo► Subscribe► Subscribe► Subscribe
Teva Pharms Usa
GRANISETRON HYDROCHLORIDE
granisetron hydrochloride
INJECTABLE;INJECTION078392-001Dec 31, 2007APRXNoYes► Subscribe► Subscribe► Subscribe
Heron Theraps Inc
SUSTOL
granisetron
INJECTION, EXTENDED RELEASE;SUBCUTANEOUS022445-001Aug 9, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Akorn Inc
GRANISETRON HYDROCHLORIDE
granisetron hydrochloride
INJECTABLE;INJECTION079078-001Sep 14, 2009APRXNoNo► Subscribe► Subscribe► Subscribe
Pediatrx
GRANISOL
granisetron hydrochloride
SOLUTION;ORAL078334-001Feb 28, 2008DISCNNoNo► Subscribe► Subscribe► Subscribe
Bionpharma Inc
GRANISETRON HYDROCHLORIDE
granisetron hydrochloride
INJECTABLE;INJECTION078880-001Jun 30, 2008APRXNoNo► Subscribe► Subscribe► Subscribe
Fresenius Kabi Usa
GRANISETRON HYDROCHLORIDE
granisetron hydrochloride
INJECTABLE;INJECTION078522-001Dec 31, 2007APRXNoNo► Subscribe► Subscribe► Subscribe
Heron Theraps Inc
SUSTOL
granisetron
INJECTION, EXTENDED RELEASE;SUBCUTANEOUS022445-001Aug 9, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Roche
KYTRIL
granisetron hydrochloride
INJECTABLE;INJECTION020239-001Dec 29, 1993DISCNYesNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: granisetron

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,861,068 Pharmaceutical compositions using semi-solid delivery vehicle► Subscribe
8,252,306Process for preparing a semi-solid delivery vehicle comprising granisetron► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: granisetron

Country Document Number Estimated Expiration
European Patent Office2902012► Subscribe
European Patent Office1796629► Subscribe
EcuadorSP055953► Subscribe
Spain2287695► Subscribe
Japan6057972► Subscribe
World Intellectual Property Organization (WIPO)2004069141► Subscribe
Canada2579297► Subscribe
South Korea20050116365► Subscribe
Hong Kong1213477► Subscribe
China1747724► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Farmers Insurance
Fish and Richardson
Moodys
Merck
McKesson
Boehringer Ingelheim
Dow
Colorcon
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot